var data={"title":"Insulin lispro: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Insulin lispro: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7862?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=insulin-lispro-patient-drug-information\" class=\"drug drug_patient\">see &quot;Insulin lispro: Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=insulin-lispro-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Insulin lispro: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50707940\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Insulin Pen Safety Alert</span>\n      <span class=\"collapsible-date\">October 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The Institute for Safe Medication Practices (ISMP) National Medication Errors Reporting Program (MERP) has issued a safety alert regarding reports of patients incorrectly using insulin pens at home, resulting in severe cases of hyperglycemia. Patients were not removing the inner cover of a standard insulin pen needle prior to attempting to administer the insulin, and thus were not receiving insulin doses.</p>\n        <p style=\"text-indent:0em;\">Health care professionals should instruct patients on the proper use of insulin pens and require patient demonstration to verify understanding. They should also verify which pen needles patients will be using at home, either standard pens or pens with automatic needle retraction devices, and tailor instruction accordingly.</p>\n        <p style=\"text-indent:0em;\">More information can be found at http://www.ismp.org/NAN/files/NAN-20171012.pdf.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127784\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Admelog;</li>\n      <li>Admelog SoloStar;</li>\n      <li>HumaLOG;</li>\n      <li>HumaLOG Junior KwikPen;</li>\n      <li>HumaLOG KwikPen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127785\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Humalog;</li>\n      <li>HumaLOG KwikPen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127789\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Insulin, Rapid-Acting</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127828\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Insulin lispro is a rapid-acting insulin analog which is normally administered SubQ as a premeal component of the insulin regimen or as a continuous SubQ infusion and should be used with intermediate- or long-acting insulin. When compared to insulin regular, insulin lispro has a more rapid onset and shorter duration of activity. In carefully controlled clinical settings with close medical supervision and monitoring of blood glucose and potassium, insulin lispro U 100 (100 units/mL) may also be administered IV in some situations; insulin lispro U 200 (200 units/mL) may <b>not</b> be administered IV. Insulin requirements vary dramatically between patients and dictate frequent monitoring and close medical supervision. When switching between insulin lispro products (eg, Humalog, Admelog), continue with the same insulin dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Diabetes mellitus, type 1:</b> SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General insulin dosing (off-label):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Type 1: <b>Note:</b> Multiple daily doses or continuous subcutaneous infusions guided by blood glucose monitoring are the standard of diabetes care. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the <b>total units/kg/day of all insulin formulations combined.</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Initial total insulin dose:</b> 0.2 to 0.6 units/kg/day in divided doses. Conservative initial doses of 0.2 to 0.4 units/kg/day are often recommended to avoid the potential for hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Usual maintenance range:</b> 0.5 to 1 units/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Nonobese: 0.4 to 0.6 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Obese: 0.8 to 1.2 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Division of daily insulin requirement (&ldquo;conventional therapy&rdquo;):</b> Generally, 50% to 75% of the total daily dose (TDD) is given as an intermediate- or long-acting form of insulin (in 1 to 2 daily injections). The remaining portion of the TDD is then divided and administered before or at mealtimes (depending on the formulation) as a rapid-acting (eg, lispro, aspart, glulisine) or short-acting (regular) form of insulin. Some patients may benefit from the use of CSII which delivers rapid-acting insulin as a continuous infusion throughout the day and as boluses at mealtimes via an external pump device.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Division of daily insulin requirement (&ldquo;intensive therapy&rdquo;):</b> Basal insulin delivery with 1 or 2 doses of intermediate- or long-acting insulin formulations superimposed with doses of short-acting (regular) or rapid-acting insulin (eg, lispro, aspart, glulisine) formulations 3 or more times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Dosage adjustment:</b> Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component. Treatment and monitoring regimens must be individualized. Also see Additional Information or Pharmacotherapy Pearls.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Continuous SubQ insulin infusion (insulin pump):</b> A combination of a &quot;basal&quot; continuous insulin infusion rate with preprogrammed, premeal bolus doses which are patient controlled. When converting from multiple daily SubQ doses of maintenance insulin, it is advisable to reduce the basal rate to less than the equivalent of the total daily units of the longer acting insulin (eg, NPH); divide the total number of units by 24 to get the basal rate in units/hour. Do not include the total units of regular insulin or other rapid-acting insulin formulations in this calculation. The same prandial insulin dosage may be used empirically.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Diabetes mellitus, type 2:</b> SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Off-label:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial:</i> 4 units <b>or</b> 0.1 unit/kg <b>or</b> 10% of the <b>basal</b> insulin dose; insulin lispro (ie, a rapid acting insulin) is administered before the largest meal of the day and is usually given in addition to a regimen that includes <b>basal</b> insulin (ie, a long-acting insulin such as glargine, degludec, or detemir) and metformin +/- other noninsulin agents. If HbA<sub>1c</sub> is still not controlled despite titrations to reach glycemic targets, one option is to advance to &lsquo;basal-bolus&rsquo; (ie, insulin lispro administered before &ge;2 meals per day) in addition to <b>basal</b> insulin and usually given in addition to metformin +/- other noninsulin agent (ADA 2017f).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage adjustment: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">To reach self-monitoring glucose target: Adjust dose by 10% to 15% <b>or</b> 1 to 2 units; may adjust at weekly or twice weekly intervals (ADA 2017f)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">For hypoglycemia: If no clear reason for hypoglycemia, decrease dose by 2 to 4 units <b>or </b>by 10% to 20% (ADA 2017f)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Surgical patients</i>: On the morning of surgery or procedure, give 60% to 80% of the usual dose of long-acting analogs (eg, detemir, glargine, or degludec) or pump &ldquo;basal&rdquo; insulin (rapid-or short-acting insulins) (ADA 2017d)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General considerations for insulin use in type 2 diabetes:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Timing of initiation:</i> Dual therapy (metformin + a second antihyperglycemic agent) and then triple therapy (metformin + two antihyperglycemic agents) is recommended in patients who fail to achieve glycemic goals after ~3 months with lifestyle intervention and metformin monotherapy or dual therapy, respectively (unless contraindications to metformin exist). Preference is not given for which agent(s) should be added to metformin (drug choice should be individualized based on patient characteristics). If HbA<sub>1c</sub> target not achieved after ~3 months of triple therapy, consider initiating basal insulin (usually with metformin +/- other noninsulin agent) or if patient already receiving an optimally titrated <b>basal</b> insulin (ie, a long-acting insulin such as glargine, degludec, or detemir) as part of their regimen, consider combination injectable therapy (ADA 2017f).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Combination injectable therapy:</i> If HbA<sub>1c</sub> target has not been met with <b>basal </b>insulin (ie, long-acting insulin such as glargine, degludec or detemir) (usually combined with metformin +/- other noninsulin agent), despite titrating <b>basal</b> insulin to provide acceptable fasting blood glucose concentrations, combination injectable therapy should be considered. Options include: adding a rapid-acting insulin (eg, lispro, aspart, glulisine) prior to largest meal <b>or</b> adding a GLP-1 receptor agonist <b>or</b> changing from <b>basal </b>insulin to a twice daily premixed insulin. If HbA<sub>1c </sub>still not adequately controlled, consider advancing from one rapid-acting insulin prior to largest meal to &lsquo;basal-bolus&rsquo; regimen (ie, rapid-acting insulin administered before &ge;2 meals) <b>or</b> consider advancing from a twice daily premixed insulin to a three times daily premixed insulin (ADA 2017f).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients with elevated HbA<sub>1C</sub> at therapy initiation:</i> If HbA<sub>1c</sub> is &ge;9% at initiation of therapy, dual therapy (metformin + a second antihyperglycemic agent) should be considered. If HbA<sub>1c</sub> &ge;10%, blood glucose is &ge;300 mg/dL or if patient is symptomatic (eg, polyuria, polydipsia), insulin therapy (with or without additional agents) should be considered (ADA 2017f).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Diabetic ketoacidosis, mild-to-moderate (off-label use):</b> SubQ: Initial: 0.3 units/kg, followed by 0.1 units/kg every hour until blood glucose &lt;250 mg/dL, then decrease to 0.05 units/kg/hour until resolution of ketoacidosis (Umpierrez 2004). Also, refer to institution-specific protocols where appropriate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127827\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=insulin-lispro-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Insulin lispro: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Insulin lispro is a rapid-acting insulin analog that is normally administered SubQ as a premeal component of the insulin regimen or as a continuous SubQ infusion and should be used with intermediate- or long-acting insulin. When compared to insulin regular, insulin lispro has a more rapid onset and shorter duration of activity. In carefully controlled clinical settings with close medical supervision and monitoring of blood glucose and potassium, insulin lispro may also be administered IV in some situations; insulin requirements vary dramatically between patients and dictate frequent monitoring and close medical supervision. See Insulin Regular for additional information. When switching between insulin lispro products (eg, Humalog, Admelog), continue with the same insulin dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General insulin dosing (off-label):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diabetes mellitus, type 1:</b> Children and Adolescents: <b>Note:</b> Multiple daily doses or continuous subcutaneous infusions guided by blood glucose monitoring are the standard of diabetes care. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the <b>total units/kg/day of all insulin formulations combined</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Initial dose:</b> SubQ: 0.2 to 0.6 units/kg/day in divided doses. Conservative initial doses of 0.2 to 0.4 units/kg/day are often recommended to avoid the potential for hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Usual maintenance range:</b> SubQ: 0.5 to 1 unit/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Nonobese: 0.4 to 0.6 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Obese: 0.8 to 1.2 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pubescent Children and Adolescents: During puberty, requirements may substantially increase to &gt;1 unit/kg/day and in some cases up to 2 units/kg/day (IDF/ISPAD 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Dosage adjustment:</b> Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen that most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Continuous SubQ insulin infusion (insulin pump):</b> A combination of a &quot;basal&quot; continuous insulin infusion rate with preprogrammed, premeal bolus doses which are patient controlled. When converting from multiple daily SubQ doses of maintenance insulin, it is advisable to reduce the basal rate to less than the equivalent of the total daily units of longer-acting insulin (eg, NPH); divide the total number of units by 24 to get the basal rate in units/hour. Do not include the total units of regular insulin or other rapid-acting insulin formulations in this calculation. The same prandial insulin dosage may be used empirically.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2308015\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127829\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Adults: There are no specific dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment may be needed as insulin requirements may be reduced due to changes in insulin clearance or metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8103637\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment may be needed as insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20330569\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to indication-specific dosing for obesity-related information (may not be available for all indications).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104242\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Admelog: 100 units/mL (10 mL) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HumaLOG: 100 units/mL (3 mL, 10 mL) [contains metacresol, phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Pen-injector, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Admelog SoloStar: 100 units/mL (3 mL) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HumaLOG Junior KwikPen: 100 units/mL (3 mL) [contains metacresol, phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HumaLOG KwikPen: 100 units/mL (3 mL); 200 units/mL (3 mL) [contains metacresol, phenol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127787\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127831\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Use only if solution is clear and colorless; do not use if solution is viscous, cloudy, colored, or if it has lumps or particles in it.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ administration: Insulin lispro should be administered within 15 minutes before or immediately after a meal. Cold injections should be avoided. SubQ administration is usually made into the thighs, arms, buttocks, or abdomen; rotate injection sites within the same region to avoid lipodystrophy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Humalog: </i>Do not dilute or mix other insulins with insulin lispro contained in a cartridge or prefilled pen. Do not mix insulin lispro U 200 with any other insulin. May mix insulin lispro U 100 (eg, 100 units/mL) from a vial only with insulin NPH (do not mix with other types of insulin); insulin lispro should be drawn into syringe first; perform injection immediately. Kwikpens are designed to dial doses in 1-unit increments (U-100 or U-200 pens) or in 0.5-unit increments (Junior KwikPen). Do not perform dose conversion when using Humalog KwikPen devices; the dose window shows the number of units to be delivered and no conversion is needed. Do not transfer insulin lispro U 200 KwikPen to a syringe for administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Admelog: </i>Do not mix with any other insulin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CSII administration: Only administer insulin lispro U 100 (eg, 100 units/mL) via CSII; do not administer insulin lispro U 200 (eg, 200 units/mL) in a CSII pump. Patients should be trained in the proper use of their external insulin pump and in intensive insulin therapy. Infusion sets and infusion set insertion sites should be changed every 3 days; rotate infusion sites. Insulin in reservoir should be changed at least every 7 days. Do not dilute or mix other insulins with insulin lispro U 100 (eg, 100 units/mL) contained in an external insulin pump.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV administration: May be administered IV with close monitoring of blood glucose and serum potassium; appropriate medical supervision is required. Do not administer insulin lispro U 200 (200 units/mL) IV. <b>Do not administer insulin mixtures IV.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV infusions: To minimize adsorption to IV tubing: At low concentrations and flow rates, insulin lispro has been shown to adsorb to PVC IV bags and tubing (Ling 1999). Therefore, flush the IV tubing with a priming infusion of 20 mL from the insulin infusion, whenever a new IV tubing set is added to the insulin infusion container (SCCM [Jacobi 2012; Thompson 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Also refer to institution-specific protocols where appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Because of insulin adsorption to IV tubing or infusion bags, the actual amount of insulin being administered via IV infusion could be substantially less than the apparent amount. Therefore, adjustment of the IV infusion rate should be based on effect and not solely on the apparent insulin dose. The apparent dose may be used as a starting point for determining the subsequent SubQ dosing regimen (Moghissi 2009); however, the transition to SubQ administration requires continuous medical supervision, frequent monitoring of blood glucose, and careful adjustment of therapy. Transition to a protocol-driven basal/bolus insulin regimen should begin prior to stopping the IV infusion in order to avoid significant loss of glucose control (Jacobi 2012; Moghissi 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127792\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diabetes mellitus, types 1 and 2:</b> Treatment of type 1 diabetes mellitus and type 2 diabetes mellitus to improve glycemic control</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25726566\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Diabetic ketoacidosis (mild-to-moderate); Gestational diabetes mellitus; Mild-to-moderate hyperosmolar hyperglycemic state (HHS)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127781\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">HumaLOG may be confused with HumaLOG Mix 50/50, Humira, HumuLIN N, HumuLIN R, NovoLOG</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Humapen Memoir (used with HumaLOG) may be confused with the Humira Pen</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. <b><i>Due to the number of insulin preparations, it is essential to identify/clarify the type and strength of insulin to be used.</i></b></p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Insulin (short- or rapid-acting insulin products used for sliding scale) is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to higher risk of hypoglycemia associated with sliding scale insulin without improvements in hyperglycemia, regardless of care setting. Recommendation pertains to the sole use of short- or rapid-acting insulins in the absence of basal or long-acting insulin; recommendation does not apply to the titration of basal insulin or the use of additional short- or rapid-acting insulin in conjunction with scheduled insulin (ie, correction insulin) (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127803\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Severe hypoglycemia (2% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (type 2 diabetics; 19%; type 1 diabetics: 23%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Infusion site reaction (type 1 diabetes: 21% to 24%; includes erythema and occlusion)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: Neuromuscular &amp; skeletal: Myalgia (7%; most likely secondary to excipient metacresol)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypoglycemia, hypokalemia, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Hypertrophy at injection site, injection site reaction (including local reactions secondary to excipient metacresol), lipoatrophy at injection site</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127798\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to insulin lispro or any component of the formulation; during episodes of hypoglycemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127799\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glycemic control: The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from changes in meal pattern (eg, macronutrient content or timing of meals), changes in the level of physical activity, increased work or exercise without eating or changes to coadministered medications. Hyperglycemia is also a concern; may occur with CSII pump or infusion set malfunctions or insulin degradation; hyper- or hypoglycemia may result from changes in insulin strength, manufacturer, type or administration method. Use of long-acting insulin preparations (eg, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Patients with renal or hepatic impairment may be at a higher risk. Symptoms differ in patients and may change over time in the same patient; awareness may be less pronounced in those with long standing diabetes, diabetic nerve disease, patients taking beta-blockers or in those who experience recurrent hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage, or even death. Insulin requirements may be altered during illness, emotional disturbances, or other stressors. Instruct patients to use caution with ethanol; may increase risk of hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions (serious, life-threatening and anaphylaxis) have occurred. If hypersensitivity reactions occur, discontinue administration and initiate supportive care measures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: Insulin (especially IV insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium frequently with IV insulin use and supplement potassium when necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage requirements may be reduced and patients may require more frequent dose adjustment and glucose monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Dosage requirements may be reduced and patients may require more frequent dose adjustment and glucose monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hospitalized patients with diabetes: Exclusive use of a sliding scale insulin regimen (insulin regular) in the inpatient hospital setting is strongly discouraged. In the critical care setting, continuous IV insulin infusion (insulin regular) has been shown to best achieve glycemic targets. In noncritically ill patients with either poor oral intake or taking nothing by mouth, <b>basal </b>insulin or <b>basal</b> plus bolus is preferred. In noncritically ill patients with adequate nutritional intake, a combination of <b>basal </b>insulin, nutritional, and correction components is preferred. An effective insulin regimen will achieve the goal glucose range without the risk of severe hypoglycemia). A blood glucose value &lt;70 mg/dL should prompt a treatment regimen review and change, if necessary, to prevent further hypoglycemia (ADA 2017d).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Humalog KwikPen devices: Do not perform dose conversion when using KwikPen; the dose window shows the number of units to be delivered and no conversion is needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Humalog U 200 (200 units/mL) KwikPen: Do not transfer product from the KwikPen to a syringe for administration. Do not mix with other insulins, administer in a CSII pump, or administer IV.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple-dose injection pens: According to the CDC, pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Diabetes mellitus: The general objective of exogenous insulin therapy is to approximate the physiologic pattern of insulin secretion which is characterized by two distinct phases. Phase 1 insulin secretion suppresses hepatic glucose production and phase 2 insulin secretion occurs in response to carbohydrate ingestion; therefore, exogenous insulin therapy may consist of basal insulin (eg, intermediate- or long-acting insulin via continuous subcutaneous insulin infusion [CSII]) and/or preprandial insulin (eg, short- or rapid-acting insulin [eg, insulin lispro]) (see Related Information: Insulin Products). Patients with type 1 diabetes do not produce endogenous insulin; therefore, these patients require both basal and preprandial insulin administration. Patients with type 2 diabetes retain some beta-cell function in the early stages of their disease; however, as the disease progresses, phase 1 insulin secretion may become completely impaired and phase 2 insulin secretion becomes delayed and/or inadequate in response to meals. Therefore, patients with type 2 diabetes may be treated with oral antidiabetic agents, basal insulin, and/or preprandial insulin depending on the stage of disease and current glycemic control. Since treatment regimens often consist of multiple agents, dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient's impaired glycemic control. Treatment and monitoring regimens must be individualized.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Due to the short duration of action of insulin lispro, a longer acting insulin or CSII via an external insulin pump is needed to maintain adequate glucose control in patients with type 1 diabetes mellitus. In both type 1 and type 2 diabetes, preprandial administration of insulin lispro should be immediately followed by a meal within 15 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CSII administration: Insulin lispro U-100 (eg, 100 units/mL) may be administered via CSII; do not dilute or mix with other insulins. Rule out external pump failure if unexplained hyperglycemia or ketosis occurs; temporary SubQ insulin administration may be required until the problem is identified and corrected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IV administration: Insulin lispro U 100 (eg, 100 units/mL) may be administered IV in selected clinical situations to control hyperglycemia; close monitoring of blood glucose and serum potassium as well as medical supervision is required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127810\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127809\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9025&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the hypoglycemic effect of Insulins.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edetate Disodium: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Insulins. Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Avoid the use of lixisenatide in patients receiving  both basal insulin and a sulfonylurea.<b> Exceptions: </b>Liraglutide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liraglutide: May enhance the hypoglycemic effect of Insulins. Management: If liraglutide is used for the treatment of diabetes (Victoza), consider insulin dose reductions. The combination of liraglutide and insulin should be avoided if liraglutide is used exclusively for weight loss (Saxenda).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Insulins may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metreleptin: May enhance the hypoglycemic effect of Insulins. Management: Insulin dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pioglitazone: May enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination. Management: If insulin is combined with pioglitazone, dose reductions should be considered to reduce the risk of hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the hypoglycemic effect of Insulins. Management: Upon initiation of pramlintide, decrease mealtime insulin dose by 50% to reduce the risk of hypoglycemia. Monitor blood glucose frequently and individualize further insulin dose adjustments based on glycemic control.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosiglitazone: Insulins may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium-Glucose Cotransporter 2 (SLGT2) Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127793\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127794\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have not been observed in animal reproduction studies. Insulin lispro has not been shown to cross the placenta at standard clinical doses (Boskovic 2003; Holcberg 2004; Jovanovic 1999).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In women with diabetes, maternal hyperglycemia can be associated with congenital malformations as well as adverse effects in the fetus, neonate, and the mother (ACOG 2005; ADA 2017c; Kitzmiller 2008; Metzger 2007). To prevent adverse outcomes, prior to conception and throughout pregnancy maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ACOG 2013; ADA 2017c; Blumer 2013; Kitzmiller 2008; Lambert 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28 to 32 weeks' gestation. Following delivery, insulin requirements decrease rapidly (ACOG 2005).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Insulin therapy is the preferred treatment of type 1 and type 2 diabetes in pregnant women, as well as GDM when pharmacologic therapy is needed (ADA 2017c). Insulin lispro may be used to treat diabetes in pregnant women (ACOG 2013; Blumer 2013; Kitzmiller 2008; Lambert 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127797\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Both exogenous and endogenous insulin are present in breast milk (study not conducted with this preparation) (Whitmore 2012). Breastfeeding is encouraged for all women, including those with type 1, type 2, or GDM (ACOG 2005; ADA 2017c; Blumer 2013; Metzger 2007). A small snack (such as milk) before breastfeeding may help decrease the risk of hypoglycemia in women with pregestational diabetes (ACOG 2005; Reader 2004). All types of insulin may be used while breastfeeding (Metzger 2007). The manufacturer considers the use of insulin lispro to be compatible with breastfeeding, although adjustments of the mothers insulin dose may be needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127830\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127833\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diabetes mellitus: Plasma glucose, electrolytes, HbA<sub>1c</sub> (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change [ADA 2017a]); renal function, hepatic function, weight</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV administration: Close monitoring of blood glucose and serum potassium</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127818\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for glycemic control in nonpregnant adults with diabetes (ADA 2017a):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 80 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak postprandial capillary blood glucose: &lt;180 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Recommendations for glycemic control in older adults (&ge;65 years) with diabetes (ADA 2017b):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7.5% (healthy); &lt;8% (complex/intermediate health); &lt;8.5% (very complex/poor health) (individualization may be appropriate based on patient and caregiver preferences)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 90 to 130 mg/dL (healthy); 90 to 150 mg/dL (complex/intermediate health); 100 to 180 mg/dL (very complex/poor health)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bedtime capillary blood glucose: 90 to 150 mg/dL (healthy); 100 to 180 mg/dL (complex/intermediate health); 110 to 200 mg/dL (very complex/poor health)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Recommendations for glycemic control in pediatric (all age groups) patients with type 1 diabetes (ADA 2017e):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7.5% (individualization may be appropriate based on patient-specific characteristics; &lt;7% is reasonable if it can be achieved without excessive hypoglycemia)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 90 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bedtime and overnight capillary blood glucose: 90 to 150 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for hospitalized adult patients with diabetes (ADA 2017d): Target glucose range: 140 to 180 mg/dL (majority of critically ill and noncritically ill patients; &lt;140 mg/dL may be appropriate for selected patients, if it can be achieved without excessive hypoglycemia). Initiate insulin therapy for persistent hyperglycemia at &ge;180 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for perioperative care in adult patients with diabetes (ADA 2017d): Target glucose range during perioperative period: Consider targeting 80 to 180 mg/dL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127816\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes; also directly inhibits the hydrolysis of triglycerides. In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either <i>E. coli</i> or <i>Saccharomyces cerevisiae</i>. Insulin lispro differs from human insulin by containing a lysine and proline at positions B28 and B29, respectively, in comparison to the proline and lysine found at B28 and B29 in human insulin. Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin lispro is a rapid-acting insulin analog.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127819\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Onset and duration of hypoglycemic effects depend upon the route of administration (adsorption and onset of action are more rapid after deeper IM injections than after SubQ), site of injection (onset and duration are progressively slower with SubQ injection into the abdomen, arm, buttock, or thigh respectively), volume and concentration of injection, and the preparation administered. Rate of absorption, onset, and duration of activity may be affected by exercise, presence of lipodystrophy, local blood supply, and/or temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Onset of action: SubQ: 0.25-0.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: SubQ: 0.5-2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: SubQ: &le;5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: IV: 0.72-1.55 L/kg (inversely related to dose) </p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Bioavailability: 55% to 77%</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Half-life elimination: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: SubQ: 0.5-1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422168\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Admelog Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (10 mL): $280.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (HumaLOG Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (3 mL): $98.89</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Cartridge</b> (HumaLOG Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (3 mL): $122.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Pen-injector</b> (Admelog SoloStar Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (3 mL): $108.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Pen-injector</b> (HumaLOG Junior KwikPen Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (3 mL): $127.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Pen-injector</b> (HumaLOG KwikPen Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (3 mL): $127.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 units/mL (3 mL): $254.59</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869462\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Humalog (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CY, CZ, DE, DK, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HN, HR, HU, ID, IE, IN, IS, IT, JM, JP, KE, KW, LB, LK, LR, LT, LU, LV, MA, ML, MR, MT, MU, MW, MX, NE, NG, NL, NO, PK, PT, PY, QA, RO, RU, SA, SC, SD, SE, SI, SK, SL, SN, SR, TH, TN, TR, TT, TW, TZ, UG, UY, VE, ZA, ZM, ZW);</li>\n      <li>Humalog Lispro (CR, GT, HN, IL, KR, NI, PA, PE, SV);</li>\n      <li>Humalog Miriopen (JP);</li>\n      <li>Humalog Mix NPL (AT, BE, BG, CH, CZ, DE, DK, FI, FR, GB, GR, HN, IE, IT, NL, NO, PT, RU, SE, TR);</li>\n      <li>Humaloh (UA);</li>\n      <li>Insul Lispro (BD);</li>\n      <li>Insulin Humalog (PL);</li>\n      <li>Insuline Lispro Humalog (FR);</li>\n      <li>Liprolog (AT, BE, BG, CH, CZ, DE, DK, FI, FR, GB, GR, HN, IE, IT, NL, NO, PT, RU, SE, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Admelog (insulin lispro) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Admelog (insulin lispro) [product monograph]. Laval, Quebec, Canada: Sanofi-aventis Canada Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational Diabetes Mellitus. <i>Obstet Gynecol</i>. 2005; 105(3):675-685.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/15738045/pubmed\" target=\"_blank\" id=\"15738045\">15738045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23969827\"></a>American College of Obstetricians and Gynecologists (ACOG), Committee on Practice Bulletins--Obstetrics. Practice Bulletin No. 137: Gestational diabetes mellitus. <i>Obstet Gynecol</i>. 2013;122(2 Pt 1):406-416.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/23969827 /pubmed\" target=\"_blank\" id=\"23969827 \">23969827 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27979893\"></a>American Diabetes Association (ADA). 6. Glycemic targets. <i>Diabetes Care</i>. 2017a;40(suppl 1):S48&ndash;S56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/27979893/pubmed\" target=\"_blank\" id=\"27979893\">27979893</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 11. Older adults. <i>Diabetes Care</i>. 2017b;40(suppl 1):S99&ndash;S104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/27979898/pubmed\" target=\"_blank\" id=\"27979898\">27979898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27979900\"></a>American Diabetes Association (ADA). 13. Management of diabetes in pregnancy. <i>Diabetes Care</i>. 2017c;40(suppl 1):S114-S119.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/27979900/pubmed\" target=\"_blank\" id=\"27979900\">27979900</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 14. Diabetes care in the hospital. <i>Diabetes Care</i>. 2017d;40(suppl 1):S120&ndash;S127.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/27979901/pubmed\" target=\"_blank\" id=\"27979901\">27979901</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 12. Children and adolescents. <i>Diabetes Care</i>. 2017e;40(suppl 1):S105&ndash;S113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/27979899/pubmed\" target=\"_blank\" id=\"27979899\">27979899</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 8. Pharmacologic approaches to glycemic treatment. <i>Diabetes Care.</i> 2017f;40(suppl 1):S64&ndash;S74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/27979895/pubmed\" target=\"_blank\" id=\"27979895\">27979895</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24194617\"></a>Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/24194617 /pubmed\" target=\"_blank\" id=\"24194617 \">24194617 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boskovic R, Feig DS, Derewlany L, et al. Transfer of insulin lispro across the human placenta: <i>In vitro</i> perfusion studies. <i>Diabetes Care</i>. 2003; 26(5):1390-1394.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/12716794/pubmed\" target=\"_blank\" id=\"12716794\">12716794</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. <a href=\"http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html\" target=\"_blank\">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed January 9, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holcberg G, Tsadkin-Tamir M, Sapir O, et al. Transfer of insulin lispro across the human placenta. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2004; 115(1):117-118.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/15223182/pubmed\" target=\"_blank\" id=\"15223182\">15223182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Humalog (insulin lispro injection [rDNA origin] solution) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    International Diabetes Federation, International Society for Pediatric and Adolescent Diabetes. Global IDF/ISPAD Guideline for Diabetes in Childhood and Adolescence. 2011. Available at http://www.idf.org/e-library/guidelines/80-the-global-idf-ispad-guidelines-for-diabetes-in-childhood-and-adolescence.html. Last accessed: April 27 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i>. 2015;38(1):140-149.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/25538310/pubmed\" target=\"_blank\" id=\"25538310\">25538310</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23164767\"></a>Jacobi J, Bircher N, Krinsley J, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. <i>Crit Care Med</i>. 2012;40(12):3251-3276.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/23164767/pubmed\" target=\"_blank\" id=\"23164767\">23164767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10480503\"></a>Jovanovic L, Ilic S, Pettitt DJ, et al. Metabolic and immunologic effects of insulin lispro in gestational diabetes. <i>Diabetes Care</i>. 1999;22(9):1422-1427.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/10480503/pubmed\" target=\"_blank\" id=\"10480503\">10480503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kirkman M, Briscoe VJ, Clark N, et al. Diabetes in older adults: A consensus report. <i>J Am Geriatr Soc</i>. 2012; doi: 10.1111/jgs.12035.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/23106132/pubmed\" target=\"_blank\" id=\"23106132\">23106132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kitabchi AE, Umpierrez GE, Miles JM, et al. Hyperglycemic crises in adult patients with diabetes. <i>Diabetes Care</i>. 2009; 32(7):1335-1343.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/19564476/pubmed\" target=\"_blank\" id=\"19564476\">19564476</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18445730\"></a>Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. <i>Diabetes Care</i>. 2008;31(5):1060-1079.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/18445730/pubmed\" target=\"_blank\" id=\"18445730\">18445730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lambert K, Holt RI. The use of insulin analogues in pregnancy.<i> Diabetes Obes Metab</i>. 2013;15(10):888-900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/23489521 /pubmed\" target=\"_blank\" id=\"23489521 \">23489521 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10531849\"></a>Ling J, Hu M, Hagerup T, et al. Lispro insulin: adsorption and stability in selected intravenous devices. <i>Diabetes Educ</i>. 1999;25(2):237-245.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/10531849/pubmed\" target=\"_blank\" id=\"10531849\">10531849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metzger BE, Buchanan TA, Coustan DR, et al. Summary and recommendations of the fifth International workshop-conference on gestational diabetes mellitus,&quot; <i>Diabetes Care</i>. 2007, 30(Suppl 2):251-260.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/17596481/pubmed\" target=\"_blank\" id=\"17596481\">17596481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control. <i> Endocr Pract</i>. 2009;15(4):353-369.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/19454396/pubmed\" target=\"_blank\" id=\"19454396\">19454396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. <i>Curr Diab Rep</i>. 2004;4(5):370-376.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/15461903/pubmed\" target=\"_blank\" id=\"15461903\">15461903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22746979\"></a>Thompson CD, Vital-Carona J, Faustino EV. The effect of tubing dwell time on insulin adsorption during intravenous insulin infusions. <i>Diabetes Technol Ther</i>. 2012;14(10):912-916.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/22746979/pubmed\" target=\"_blank\" id=\"22746979\">22746979</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15277410\"></a>Umpierrez GE, Cuervo R, Karabell A, et al. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. <i>Diabetes Care</i>. 2004; 27(8):1873-1878.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/15277410/pubmed\" target=\"_blank\" id=\"15277410\">15277410</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15336577\"></a>Umpierrez GE, Latif K, Stoever J, et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. <i>Am J Med</i>. 2004;117(5):291-296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/15336577/pubmed\" target=\"_blank\" id=\"15336577\">15336577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whitmore TJ, Trengove NJ, Graham DF, Hartmann PE. Analysis of insulin in human breast milk in mothers with type 1 and type 2 diabetes mellitus. <i>Int J Endocrinol</i>. 2012;2012:296368.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-lispro-drug-information/abstract-text/22500167/pubmed\" target=\"_blank\" id=\"22500167\">22500167</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9025 Version 182.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50707940\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F2127784\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F2127785\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F2127789\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F2127828\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F2127827\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F2308015\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F2127829\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F8103637\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20330569\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F2104242\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F2127787\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2127831\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2127792\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25726566\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2127781\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F2127803\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F2127798\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F2127799\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F2127810\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F2127809\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F2127793\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2127794\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F2127797\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F2127830\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2127833\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F2127818\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F2127816\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F2127819\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422168\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F2869462\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9025|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=insulin-lispro-patient-drug-information\" class=\"drug drug_patient\">Insulin lispro: Patient drug information \t</a></li><li><a href=\"topic.htm?path=insulin-lispro-pediatric-drug-information\" class=\"drug drug_pediatric\">Insulin lispro: Pediatric drug information</a></li></ul></div></div>","javascript":null}